This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The
study hypothesis is that the SR580 applicator will improve the appearance of Striae
Distensae by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months
follow-up compared to baseline in at least 50% of the study population.
Study Design This is a multi-site, prospective, open labeled clinical trial with
before-after study design. This study will include up to 8 visits at the clinic: initial
screening/consultation, 5 treatments, visits in 2 week intervals, and 2 follow-up visits at
1 and 3 months after the last treatment visit.
Up to 60 healthy subjects age 24-65 with Striae Distensae will be enrolled.
Duration of subject's participation: Up to 5.5 months from enrollment to termination
Blinding Objective assessment of clinical improvement by global assessment scale will be
achieved by sending before/after pictures (baseline/3months after last treatment) to 3
blinded reviewers at the end of the study.
Study Procedures Test Spots Up to 3 test spots will be performed in the selected treatment
area to determine the optimal parameters / settings
Treatment visits Each subject will be enrolled and scheduled for 5 treatments at 2 week
intervals and return for follow-up visits at one month and 3 months after the last treatment
for evaluation of the treated areas. The duration of the entire treatment visit is
approximately 60 minutes.
Treatment The treatment areas are divided into 2 treatment areas: abdomen or thighs. Apply a
thin layer of IPL gel. Place the applicator in close contact, perpendicular to the skin with
no pressure applied. Pressing the applicator will fire the IPL pulse.
Administer pulses throughout the treated area to ensure full coverage of the treated area
with applicator overlap approximately 1/3 of the previously treated skin.
A single pass over the area is completed Remove the remnants of the IPL gel and dry
thoroughly. Cold air or cold, wet but not frozen gauze pads may be placed on the treated
area for post treatment cooling.
Typical responses to the treatment are mild erythema and edema.
1. Able to provide written Informed Consent;
2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V;
3. Having visible Striae Distensae to be treated (abdomen/thighs);
4. Comply with the treatment/follow-up schedule and requirements;
5. Women of child-bearing age are required to be using a reliable method of birth
1. Fitzpatrick-Goldman skin type VI;
2. Pregnant, intending to become pregnant during the course of study, less than 3 months
postpartum or less than 6 weeks after breastfeeding;
3. Heavy smoker
4. Unable or unlikely to refrain from tanning
5. Use of photosensitive medication
6. Use of oral isotretinoin within 3 months
7. Any dermal/epidermal damage or disorder in treated area
8. Prior treatment in treated area within 3 months
9. Prior skin laser/light or another device treatment in treated area within 6 months
10. Prior use of collagen, fat injections or other methods of skin augmentation in
treated area within 12 months
11. Prior use of Botox in treatment area within 6 months
12. Prior ablative resurfacing procedure with laser in treatment area within 12 months
13. Any other surgery in treated area within 9 months
14. Participation in a study of another investigational device or drug as per the
15. History of keloid or any other type of hypertrophic scar formation or poor wound
healing in a previously injured skin area
16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma);
17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on
area to be treated during the course of treatment
18. Active Herpes Simplex at the time of treatment or having experienced more than three
episodes of Herpes Simplex eruption within a year of study
19. Multiple dysplastic nevi in area to be treated
20. Having a bleeding disorder or taking anticoagulation medications
21. History of immunosuppression/immune deficiency disorders
22. Having any form of active cancer at the time of enrollment and during the course of
the study or history of skin cancer
23. Pigmented lesion in the treated area that appears cancerous
24. Significant concurrent illness, such as uncontrolled diabetes
25. Active infections in the treated area
28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or
evidence of active substance or alcohol abuse 30.Any condition which, in the
Investigator's opinion, would make it unsafe (for the subject or for the study personnel)
to treat the subject as part of this research study